101 related articles for article (PubMed ID: 2584142)
1. FK409, a novel vasodilator isolated from the acid-treated fermentation broth of Streptomyces griseosporeus. III. Reaction mechanism and synthesis.
Hino M; Takase S; Itoh Y; Uchida I; Okamoto M; Kohsaka M; Aoki H; Imanaka H
J Antibiot (Tokyo); 1989 Nov; 42(11):1589-92. PubMed ID: 2584142
[TBL] [Abstract][Full Text] [Related]
2. FK409, a novel vasodilator isolated from the acid-treated fermentation broth of Streptomyces griseosporeus. II. Structure of FK409 and its precursor FR-900411.
Hino M; Ando T; Takase S; Itoh Y; Okamoto M; Kohsaka M; Aoki H; Imanaka H
J Antibiot (Tokyo); 1989 Nov; 42(11):1584-8. PubMed ID: 2584141
[TBL] [Abstract][Full Text] [Related]
3. Structure and synthesis of FK409, a novel vasodilator isolated from Streptomyces as a semi-artificial fermentation product.
Hino M; Takase S; Itoh Y; Uchida I; Okamoto M; Hashimoto M; Kohsaka M
Chem Pharm Bull (Tokyo); 1989 Oct; 37(10):2864-6. PubMed ID: 2611949
[TBL] [Abstract][Full Text] [Related]
4. FK409, a novel vasodilator isolated from the acid-treated fermentation broth of Streptomyces griseosporeus. I. Taxonomy, fermentation, isolation, and physico-chemical and biological characteristics.
Hino M; Iwami M; Okamoto M; Yoshida K; Haruta H; Okuhara M; Hosoda J; Kohsaka M; Aoki H; Imanaka H
J Antibiot (Tokyo); 1989 Nov; 42(11):1578-83. PubMed ID: 2584140
[TBL] [Abstract][Full Text] [Related]
5. Tolerance to the vascular effect of a novel nitric oxide-donating vasodilator, FK409.
Isono T; Sato N; Yamamoto T; Sawada T; Yamazaki S; Miura S; Furuichi A; Ozaki R; Koibuchi Y; Ohtsuka M
Eur J Pharmacol; 1994 Aug; 260(2-3):163-8. PubMed ID: 7988640
[TBL] [Abstract][Full Text] [Related]
6. FR144420, a novel, slow, nitric oxide-releasing agent.
Kita Y; Ohkubo K; Hirasawa Y; Katayama Y; Ohno M; Nishino S; Kato M; Yoshida K
Eur J Pharmacol; 1995 Mar; 275(2):125-30. PubMed ID: 7796846
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyimine NO-donors; FK409 and derivatives.
Yoshida K; Kita Y
Curr Top Med Chem; 2005; 5(7):675-85. PubMed ID: 16101428
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409.
Kita Y; Hirasawa Y; Maeda K; Nishio M; Yoshida K
Eur J Pharmacol; 1994 May; 257(1-2):123-30. PubMed ID: 8082692
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of the novel vasodilator FK409 with those of nitroglycerin in isolated coronary artery of the dog.
Yamada H; Yoneyama F; Satoh K; Taira N
Br J Pharmacol; 1991 Jul; 103(3):1713-8. PubMed ID: 1681975
[TBL] [Abstract][Full Text] [Related]
10. A new nitric oxide (NO) releaser: spontaneous NO release from FK409.
Fukuyama S; Kita Y; Hirasawa Y; Azuma T; Sato A; Morokoshi N; Koda S; Yasuda T; Oka S; Sakurai H
Free Radic Res; 1995 Nov; 23(5):443-52. PubMed ID: 7581827
[TBL] [Abstract][Full Text] [Related]
11. Biotransformations of tocopherols by Streptomyces catenulae.
Rousseau B; Dostal L; Rosazza JP
Lipids; 1997 Jan; 32(1):79-84. PubMed ID: 9075197
[TBL] [Abstract][Full Text] [Related]
12. Renal hemodynamic and excretory responses in anesthetized rats to FK409, a novel nitric oxide donor.
Urabe K; Matsumura Y; Nishiura M; Maeda K; Morimoto S
Eur J Pharmacol; 1997 Feb; 321(2):195-200. PubMed ID: 9063688
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of spontaneous nitric oxide releasers, FK409 and its derivatives.
Fukuyama S; Hirasawa Y; Kato Y; Nishio M; Ohno M; Nishino S; Maeda K; Kato M; Kita Y
J Pharmacol Exp Ther; 1997 Jul; 282(1):236-42. PubMed ID: 9223559
[TBL] [Abstract][Full Text] [Related]
14. Vasorelaxant mechanism of the new vasodilator, FK409.
Isono T; Koibuchi Y; Sato N; Furuichi A; Nishii M; Yamamoto T; Mori J; Kohsaka M; Ohtsuka M
Eur J Pharmacol; 1993 Aug; 246(3):205-12. PubMed ID: 7901040
[TBL] [Abstract][Full Text] [Related]
15. Cardiohemodynamic effect of FK409, a novel highly potent nitrovasodilator, in anesthetized dogs.
Yamada H; Yoneyama F; Satoh K; Taira N
Eur J Pharmacol; 1991 Nov; 205(1):81-3. PubMed ID: 1812001
[TBL] [Abstract][Full Text] [Related]
16. Antianginal effects of FK409, a new spontaneous NO releaser.
Kita Y; Ozaki R; Sakai S; Sugimoto T; Hirasawa Y; Ohtsuka M; Senoh H; Yoshida K; Maeda K
Br J Pharmacol; 1994 Dec; 113(4):1137-40. PubMed ID: 7889266
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide (NO)-releasing pathway of FK409 in the presence of sulfhydryl-bearing compounds.
Fukuyama S; Azuma T; Hirasawa Y; Morokoshi N; Akama T; Koda S; Kita Y
Pharm Res; 1996 Aug; 13(8):1238-42. PubMed ID: 8865319
[TBL] [Abstract][Full Text] [Related]
18. FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty.
Seki J; Nishio M; Kato Y; Motoyama Y; Yoshida K
Atherosclerosis; 1995 Sep; 117(1):97-106. PubMed ID: 8546759
[TBL] [Abstract][Full Text] [Related]
19. FK409 inhibits both local and remote organ damage after intestinal ischaemia.
Kalia N; Brown NJ; Hopkinson K; Stephenson TJ; Wood RF; Pockley AG
J Pathol; 2002 Aug; 197(5):595-602. PubMed ID: 12210078
[TBL] [Abstract][Full Text] [Related]
20. Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners.
Kita Y; Hirasawa Y; Fukuyama S; Ohkubo K; Kato Y; Takamatsu H; Ohno M; Nishino S; Kato M; Seki J
J Pharmacol Exp Ther; 1996 Feb; 276(2):421-5. PubMed ID: 8632305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
